A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults

Clinical Infectious Diseases

Volumn 52, Issue 6, 2011, Pages 736-742

  Lazarus, Rajeka ^a   Clutterbuck, Elizabeth ^a   Yu, Ly Mee ^b   Bowman, Jaclyn ^a   Bateman, Elizabeth A ^a   Diggle, Linda ^a   Angus, Brian ^c   Peto, Tim E ^c   Beverley, Peter C ^d   Mant, David ^d   Pollard, Andrew J ^a  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

23 VALENT PLAIN POLYSACCHARIDE VACCINE; ANTIBODY; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ATTENUATION; BLOOD SAMPLING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PHASE 4 CLINICAL TRIAL; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEROTYPE; SINGLE DRUG DOSE; STREPTOCOCCUS PNEUMONIAE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VACCINATION;

AGED; ANTIBODIES, BACTERIAL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PNEUMOCOCCAL VACCINES; VACCINATION;

EID: 79953737388     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir003     Document Type: Article

References (28)

1. Health Protection Agency. Invasive pneumococcal disease incidence rate per 100,000 population by age grouping England and Wales, 1996- 2005; Epidemiological Data. Available at: http://www.hpa.org.uk/webw/ HPAweb&HPAwebStandard/HPAweb-C/1195733823380?p51 203409671876 Accessed 1 August 2010
2. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American City: a 20 year longitudinal study, 1978-1997. Am J Med 1999; 107:34S-43S. (Pubitemid 29372759)
3. Moberley SA, Holden J, Tathan DP, Andrews RM. Vaccines for preventing pneumococcal infections in adults. Cochrane Database Syst Rev 2008; 23:CD000422
4. Lottenbach KR, Mink CM, Barenkamp SJ, Anderson EL, Homan SM, Powers DC. Age-associated differences in immunoglobulin G1 (IgG1) and IgG2 subclass antibodies to pneumococcal polysaccharides following vaccination. Infect Immun 1999; 67:4935-4938. (Pubitemid 29400487)
5. O'Brien KL, Hochman M, Goldblatt D. Combined schedules of pneumococcal conjugate and polysaccharide vaccines: is hyporesponsiveness an issue? Lancet Infect Dis 2007; 7:597-606. (Pubitemid 47268225)
6. de Roux A, Schmoele-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory. Clin Infect Dis 2008; 46:1015-1023. (Pubitemid 351589866)
7. Musher DM, Rueda AM, Nahm MH, Graviss EA, Rodriguez-Barradas MC. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. J Infect Dis 2008; 198:1019-1027.
8. Lal G, Balmer P, Stanford E, Martin S, Warrington R, Borrow R. Development and validation of a nonaplex assay for the simultaneous quantitation of antibodies to nine Streptococcus pneumoniae serotypes. J Immunol Methods 2005; 296:135-147. (Pubitemid 40174747)
9. Benjamini Y, Yekutieli D. False discovery rate-adjusted multiple con- fidence intervals for selected parameters. J Am Stat Assoc 2005; 100:71-81.
10. Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R. Enhanced antibody response to pneumococcal polysaccharide vaccine after prior immunization with conjugate pneumococcal vaccine in HIV-infected adults. Vaccine 2001; 19:886-894.
11. Azburg MJ, Pelton SI, Song LY, et al; for the Pediatric AIDS Clinical Trial Group. Immunogenicity, safety, and predictors of response after pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. Pediatr Infect Dis J 2006; 25:920-929. (Pubitemid 44510587)
12. Goldblatt D, Hussain M, Andrews N, et al. Antibody responses to nasopharyngeal carriage of Streptococcus pneumoniaein adults: a longitudinal household study. J Infect Dis 2005; 192:387-393. (Pubitemid 41023116)
13. Goldblatt D, Southern J, Ashton L. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers. Pediatr Infect Dis J 2006; 25: 312-319.
14. Danilova E, Shiryayev A, Kristoffersen EK, Sjursen H. Attentuated immune response to tetanus toxoid in young healthy men protected against tetanus. Vaccine 2005; 23:4980-4983. (Pubitemid 41267026)
15. Nicolay U, Girgsdies OE, Banzhoff A, Hundt E, Jilg W. Diphtheria booster vaccination: one or two injections? Vaccine 1999; 17:2223-2228. (Pubitemid 29225673)
16. Hare ND, Smith BJ, Ballas ZK. Antibody response to pneumococcal vaccination as a function of preimmunization titer. J Allergy Clin Immunol 2009; 123:195-200.
17. Weller S, Reynaud C-A, Weill J-C. Vaccination against encapsulated bacteria in humans: paradoxes. Trends Immunol 2005; 26:85-89.
18. Shelly MA, Jacoby H, Riley GJ, Graves BT, Pichichero M, Treanor JJ. Comparison of pneumococcal polysaccharide and CRM197-conjugated pneumococcal oligosaccharide vaccines in young and elderly adults. Infect Immun 1997; 65:242-247. (Pubitemid 27010311)
19. Powers DC, Anderson EL, Lottenbach K, Mink CM. Reactogenicity and immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine in older adults. J Infect Dis 1996; 173:1014-1018. (Pubitemid 26001188)
20. Goldblatt D, Southern J, Andrews N, et al. The immunogenicity of 7-valent pneumococcal conjugate vaccine versus 23-valent polysaccharide vaccine in adults aged 50 to 80 years. Clin Infect Dis 2009; 49:1318-1325.
21. Jackson LA, Neuzil KM, Nahm MH, et al. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine 2007; 25:4029-4037. (Pubitemid 46616998)
22. Jó dar L, Butler J, Carlone G, et al. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 2003; 21:3265-3272. (Pubitemid 36694567)
23. Romero-Steiner S, Musher DM, Cetron MS, et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999; 29:281-288. (Pubitemid 29380185)
24. Schenkein JG, Park S, Nahm MH. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine 2008; 26:5521-5526.
25. Lee H, Nahm H, Kim KH. The effect of age on the response to the pneumococcal polysaccharide vaccine. BMC Infect Dis 2010; 10:60.
26. Felton LD, Kauffmann G, Prescott B, Ottinger B. Studies on the mechanism of the immunological paralysis induced in mice by pneumococcal polysaccharides. J Immunol 1955; 74:17-26.
27. Musher DM, Manof SB, Liss C, et al. Safety and antibody response, including antibody persistence for 5 years, after primary vaccination or revaccination with pneumococcal polysaccharide vaccine in middleaged and older adults. J Infect Dis 2010; 201:659-661.
28. Hak E, Sanders EA, Verheij TJ, et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth J Med 2008; 66:378-383.